Kre-Alkalyn® Buffered Creatine Awarded Third International Patent

Science For Humans #1993: Dr. Jeff Wants to Change the Direction of Bodybuilding
Science For Humans #1993: Dr. Jeff Wants to Change the Direction of Bodybuilding
February 23, 2017
Science For Humans #1997: Chasing The Pump
Science For Humans #1997: Chasing The Pump
March 4, 2017
Show all

Kre-Alkalyn® Buffered Creatine Awarded Third International Patent

March 1, 2017

FOR IMMEDIATE RELEASE

Contact: Jeff Golini, Executive Scientist
Email:  jeffg@allamericanpharmaceutical.com
Phone: 1-406-245-5793

Kre-Alkalyn® Buffered Creatine Awarded Third International Patent

Billings, MT. – Nutritional supplement manufacturer All American Pharmaceutical and Executive Scientist Dr. Jeff Golini, are proud to announce they have received yet another patent for their flagship ingredient Kre-Alkalyn®, the world’s only fully stable and buffered creatine monohydrate.

Two previous international patents were granted from Australia and New Zealand. This third international patent has been awarded by Canada (#2,488,463). To date, 31 additional patents are pending worldwide. In the U.S., Kre-Alkalyn® is protected under patent #6,399,661.

According to Dr. Golini, “Kre-Alkalyn represent a major breakthrough in performance supplementation thanks to what we call ‘pH-Correct’ creatine stabilization technology. I discovered that “buffering” creatine to pH-12 produced a stable molecule in fluids. Kre-Alkalyn is the only creatine monohydrate product with a pH of 12 because its molecules are synthesized with ‘buffering’ agents using our multi-patented manufacturing process.”

In addition to its patents, four Kre-Alkalyn® research articles, authored by Dr. Golini, have appeared in various respected peer-reviewed journals. The compound is available in numerous sports and fitness products sold worldwide.

AAP
AAP
We are a contract manufacturer who transforms raw materials into dietary supplements that create trust, loyalty, and repeat sales.

Comments are closed.